Novel non-invasive methods of insulin delivery

Expert Opinion on Drug Delivery

Volumn 9, Issue 12, 2012, Pages 1539-1558

  Soares, Sandra ^a   Costa, Ana ^a   Sarmento, Bruno ^a,b,c  

^a UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Bioavailability; Buccal; Clinical trials; Insulin; Nasal; Non invasive; Oral; Pulmonary; Transdermal

Indexed keywords

CAPSULIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; LONG ACTING INSULIN; NASULIN; PLACEBO; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG;

ABSORPTION; AREA UNDER THE CURVE; BIOEQUIVALENCE; CELLS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC PATIENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PACKAGING; DRUG SAFETY; DRY POWDER; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; HEART FUNCTION; HUMAN; HYPOGLYCEMIA; IN VIVO STUDY; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; INSULIN TREATMENT; INSURANCE; INTESTINE ABSORPTION; INTESTINE WALL; IONTOPHORESIS; KERATINOCYTE; LIPOPHILICITY; LIVER CELL; LONG TERM CARE; LUNG FUNCTION; MACROMOLECULE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; MOLECULAR WEIGHT; MUCOCILIARY CLEARANCE; MULTICENTER STUDY (TOPIC); NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; OSCILLATION; PARTICLE SIZE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; SKIN PERMEABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; WEIGHT GAIN;

ABSORPTION; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84869786430     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.737779     Document Type: Review

References (146)

1. Migdalis IN. Insulin analogs versus human insulin in type 2 diabetes. Diabetes Res Clin Pract 2011;93(Suppl 1):S102-S4
2. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77(1):1-15 (Pubitemid 46590471)
3. MannKind Corp. Web Page. Available from: http://www.mannkindcorp.com/ [Last accessed 30 July 2012]
4. Richardson PC, Boss AH. Technosphereinsulin technology. Diabetes Technol Ther 2007;9(Suppl 1):S65-72
5. Al-Qadi S, Grenha A, Carrión-Recio D, et al. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release 2012;157(3):383-90
6. Cassidy J, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere-insulin inhalation powder administration. Pharm Res 2011;28(9):2157-64
7. Leone-Bay A, Baughman R, Smutney C, Kocinsky J. Innovation in drug delivery by inhalation. In: Publishing FF, editor. Orally inhaled & nasal drug products: innovations from major delivery system developers. ONdrugDelivery; East Sussex, United Kingdom: 2010. p. 4-7
8. Angelo R, Rousseau K, Grant M, et al. Technosphere insulin: defining the role of technosphere particles at the cellular level. J Diabetes Sci Technol 2009;3(3):545-54
9. Potocka E, Cassidy JP, Haworth P, et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010;4(5):1164-73
10. Leone-Bay A, Grant M. Technosphere technology: a platform for inhaled protein therapeutics. In: ONdrugDelivery, editor. Pulmonary delivery: innovative technologies breathing new life into inhalable therapeutics. ONdrugDelivery; East Sussex, United Kingdom: 561. 8-11.
11. Marino MT, Cassidy JP. The relationship between two insulin assays used to determine bioequivalence and dose proportionality of AFREZZA insulin administered using a gen2 inhaler compared to a MedTone inhaler: simulation of clinical trials and actual data. Poster #141-RIA, presented at the Diabetes Technol Soc meeting; 2010
12. Pfützner A, Mann AE, Steiner SS. Technosphere-/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2004;4(5):589-94
13. Markey KA. MannKind Corp. Update report. Griffin Securities Equities Research; New York: 2011
14. Steiner S, Pfützner A, Wilson BR, et al. Technosphere/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocr Diab 2002;110(1):17-21 (Pubitemid 34136277)
15. Pfützner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005;2(6):1097-106 (Pubitemid 41701207)
16. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010;375(9733):2244-53
17. Potocka E, Baughman R, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 2011;51(7):1015-24
18. Heinemann L. Variability of insulin action: does it matter? Insulin 2008;3(1):37-45 (Pubitemid 351331168)
19. Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere-insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2008;2(2):2005-212
20. Rave K, Potocka E, Boss AH, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009;11(7):715-20
21. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012;14(2):163-73
22. Rossiter A, Amin N, Harris R, et al. Pulmonary safety of inhaled Technosphere-Insulin therapy in adults with diabetes using high-resolution computerized tomography of the chest. Diabetologia 2009;52(S1):abstract #921
23. Skyler JS, Hollander PA, Jovanovic L, et al. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial. Diabetes Res Clin Pract 2008;82(2):238-46
24. Neumiller JJ, Campbell RK. Technosphere(R) insulin: an inhaled prandial insulin product. BioDrugs 2010;24(3):165-72
25. Forst T, Hohberg C, Schondorf T, et al. Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. Diabetes Technol Ther 2009;11(2):87-92
26. Patton JS, Bukar JG, Eldon MA. Clinical Pharmacokinetics and Pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43(12):781-801 (Pubitemid 39382220)
27. Rave K BS, Heinemann L, Sha S, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28(5):1077-82 (Pubitemid 40616616)
28. Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL; Group. EPIS. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27(11):2622-7 (Pubitemid 39441461)
29. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27(10):2356-62 (Pubitemid 39281385)
30. Rosenstock J, Cefalu WT, Hollander PA, et al. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008;31(9):1723-8
31. Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-85 (Pubitemid 46354337)
32. Hollander P, Krasner A, Klioze S, et al. Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera 1) versus subcutaneous insulin in five controlled phase 3 trials. Diabetes Care 2007;30:2508-10 (Pubitemid 47547783)
33. Rosenstock J, Foyt H, Klioze S, et al. Inhaled human insulin (Exubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes Metab 2006;55(S1):A109-OR
34. Alabraba V, Farnsworth A, Leigh R, et al. Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months. Diabetes Technol Ther 2009;11(7):427-30
35. Van Alfen-van der Velden A, Noordam C, De Galan BE, et al. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes 2010;11(6):380-2
36. Hollander PA, Cefalu WT, Mitnick M, et al. Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. Diabetes Technol Ther 2010;12(3):185-91
37. Harper NJ, Gray S, De Groot J, et al. The design and performance of the exubera pulmonary insulin delivery system. Diabetes Technol Ther 2007;9(Suppl 1):S16-27
38. Rosenstock J, Cappelleri J, Bolinder B, Gerber R. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27(6):1318-23 (Pubitemid 38679977)
39. Gerber RA CJ, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24(9):1556-9 (Pubitemid 33716448)
40. Wollmer P, Pieber TR, Gall MA, Brunton S. Delivering needle-free insulin using AERx-iDMS (Insulin Diabetes Management System) technology. Diabetes Technol Ther 2007;9(Suppl 1):S57-64
41. Cramer JA, Okikawa J, Bellaire S, Clauson P. Compliance with inhaled insulin treatment using the AERx iDMS insulin diabetes management system. Diabetes Technol Ther 2004;6(6):800-7 (Pubitemid 40129326)
42. Mudaliar S. Inhaled insulin using AERx insulin diabetes management system (AERx iDMS). Expert Opin Investig Drugs 2007;16(10):1673-81 (Pubitemid 350028416)
43. Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44(3):305-8 (Pubitemid 32234455)
44. Moses RG, Bartley P, Lunt H, et al. Safety and efficacy of inhaled insulin (AERx-iDMS1) compared with subcutaneous insulin therapy in patients with type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med 2009;26(3):260-7
45. Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27(1):162-7 (Pubitemid 38196726)
46. Rosenstock J, Muchmore D, Swanson D, Schmitke J. AIR inhaled insulin system: a novel insulin-delivery system for patients with diabetes. Expert Rev Med Devices 2007;4(5):683-92 (Pubitemid 47496695)
47. Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther 2007(Suppl 1):S48-56
48. Muchmore DB, Silverman B, De La Peña A, Tobian J. The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther 2007(Suppl 1):S41-7
49. de La Peña A, Seger M, Rave K, et al. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technol Ther 2009(Suppl 2):S75-80
50. Gross JL, Nakano M, Colon-Vega G, et al. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol Ther 2009(Suppl 2):S27-34
51. Gross JL, Nakano M, Colon-Vega G, et al. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol Ther 2009(Suppl 2):S5-16
52. Bergenstal RM, Freemantle N, Leyk M, et al. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes? Diabetes Technol Ther 2009;11(Suppl 2):S45-52
53. Hayes RP, Muchmore D, Schmitke J. Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. Curr Med Res Opin 2007;23(2):435-42 (Pubitemid 46333391)
54. Kapitza C HT, Fishman RS, Shapiro DA, et al. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technol Ther 2004;6(2):119-27 (Pubitemid 38445737)
55. Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003;26(10):2842-7 (Pubitemid 37205556)
56. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin intrapatient variability after inhalation via the aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002;25(12):2276-81 (Pubitemid 41071040)
57. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference. Baxter International, Inc. France. 2007. Available from: www.baxter.com/press-room/press-releases/2007/04-20-07-promaxx.html [Last accessed 18 September 2012]
58. White S, Brown LR, McGeehan J, et al. The science and technology of the PROMAXX biotechnology platform. RDD Eur 2007;1:51-8
59. Rashba-Step J. Efficient pulmonary delivery of biological molecules as PROMAXX microspheres. In: ONdrugDelivery, editor. Pulmonary drug delivery: new perspectives on inhalers. ONdrugDelivery; Hove: 21-24
60. Heise T, Brugger A, Cook C, et al. PROMAXX-inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab 2009;11(5):455-9
61. Siekmeir R, Scheuch G. Inhaled Insulin-does it become reality? J Physiol Pharmacol 2008;59(6):81-113
62. Stote R, Miller M, Marbury T, et al. Enhanced absorption of Nasulin, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Technol 2011;5(1):113-19
63. Leary AC, Stote RM, Breedt HJ, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technol Ther 2005;7(1):113-19
64. Leary AC, Stote RM, Cussen K, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. Diabetes Technol Ther 2006;8(1):81-8
65. Stote R, Marbury T, Shi L, et al. Comparison pharmacokinetics of two concentrations (0.7 and 1.0) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol 2010;4(3):603-9
66. Leary AC, Dowling M, Cussen K, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol 2008;2(6):1054-60
67. CPEX Pharmaceuticals, Inc. Form 10-K Annual report: United States Securities and Exchange Commission. Washington, D.C. 20549. 2010.Available from: http://www.faqs. org/sec-filings/110331/CPEXPharmaceuticals-Inc-10-K/[Last accessed 30 July 2012]
68. Illum L. Nasal drug delivery-recent developments and future prospects. J Control Release 2012;161(2):254-63
69. CPEX Pharmaceuticals Web Page. Available from: http://www.cpexpharma. com [Last accessed 30 July 2012]
70. Marina Biotech Web Page. Available from: http://www.marinabio.com/[Last accessed 30 July 2012]
71. Benedict C, Frey Ii WH, Schioth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46(2-3):112-15
72. Schioth HB, Frey WH, Brooks SJ, Benedict C. Insulin to treat Alzheimer's disease: just follow your nose? Expert Rev Clin Pharmacol 2011;5(1):17-20
73. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
74. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Tech 2009;3(3):562-7
75. Woitiski CB, Sarmento B, Carvalho RA, et al. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011;412(1-2):123-31
76. Diabetology Web Page. Available from: http://www.diabetology.co.uk/[Last accessed 8 July 2012]
77. Luzio SD, Dunseath G, Lockett A, et al. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab 2010;12(1):82-7
78. Sabetsky V, Ekblom J. Insulin: a new era for an old hormone. Pharmacol Res 2010;61(1):1-4
79. Oramed Web Page. Available from: http://www.oramed.com/[Last accessed 8 July 2012]
80. Eldor R, Arbit E, Miteva Y, et al. Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration. American Diabetes Association. 70th Scientific Session; 2010
81. Kidron M, Eldor R, Miteva Y, et al. Extended exposure to an oral insulin formulation yields decreased insulin secretion in type II diabetes subjects. Diabetes Technology Meeting; 2010
82. Emisphere Technologies Web Page. Available from: http://www.emisphere. com/index.html [Last accessed 8 July 2012]
83. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym 2011;71(3):280-7
84. Hoffman A, Qadri B. Eligen insulin-a system for the oral delivery of insulin for diabetes. IDrugs 2008;11(6):433-41 (Pubitemid 351769410)
85. Emisphere Technologies Annual Report and Proxy. 2011.Available from: http://www. annualreports.com/HostedData/AnnualReports/PDF/EMIS2011.pdf [Last accessed 26 July 2012]
86. BOWS Pharmaceuticals AG Web Page. Available from: http://www.bowspharma. com/[Last accessed 8 July 2012]
87. ClinicTrials.gov Web Page. Available from: http://clinicaltrials.gov/ [Last accessed 9 August 2012]
88. Merrion Pharmaceuticals Web Page. Available from: http://www. merrionpharma.com/[Last accessed 8 July 2012]
89. Clinic Trials at Novo Nordisk Web Page. Available from: http://www. novonordisk-trials.com/[Last accessed 25 July 2012]
90. Diasome Pharmaceuticals Web Page. Available from: http://www.diasome.com/ [Last accessed 9 July 2012]
91. Geho WB, Geho HC, Lau JR, Gana T. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 2009;3(6):1451-9
92. Schwartz S, Geho B, Rosenberg L, Lau J. Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus. Conshohocken, PA: Diasome Pharmaceuticals and San Antonio, TX: Diabetes Glandular Research Center. 2008.Available from: http://www. diasome.com/docs/FINAL%202009% 20ADA%20Poster.pdf [Last accessed 30 July 2012]
93. Schwartz S, Geho B, Rosenberg L, Lau J. A Two-Week Randomized Active Comparator Study of Two HDV-Insulin Routes (SC and Oral) and SC Human Insulin in Patients With Type 1 Diabetes Mellitus (417-P). Poster session presented at: 68th Annual American Diabetes Association Meeting; 6-10 Jun 2008; San Francisco, Ca
94. Biocon Biopharmaceuticals Web Page. Available from: http://www.biocon. com/Last [accessed 9 July 2012]
95. Iyer H, Khedkar A, Verma M. Oral insulin-a review of current status. Diabetes Obes Metab 2010;12(3):179-85
96. Access Pharmaceuticals, Inc. Web Page. Available from: http://www.accesspharma. com [Last accessed 1 August 2012]
97. Heinemann L. New ways of insulin delivery. Int J Clin Pract 2012;66:35-9
98. Generex Biotechnology Corp. Web Page. Available from: http://www.generex.com/index.php [Last accessed 23 July 2012]
99. Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007;59:1521-46 (Pubitemid 350122777)
100. Kumria R, Goomber G. Emerging trends in insulin delivery: buccal route. J Diabetol 2011;2(1):1-9
101. Kinesh VP, Neelam DP, Punit BP, et al. Novel approaches for oral delivery of insulin and current status of oral insulin products. IJPSN 2010;3(3):1057-64
102. Monosol Rx Web Page. Available from: http://www.monosolrx.com/[Last accessed 3 August 20102]
103. Midatech Ltd. Available from: http://www.midatechgroup.com/[Last accessed 3 August 2012]
104. Zubaerova DK, Larionova NI. Noninvasive insulin delivery systems. biochemistry (Moscow) supplement series B. Biomed Chem 2008;2(4):346-55
105. Jain A, Dhote V, Dhongade H, et al. Microneedles: a revolution of transdermal drug delivery. PR 2008;6(3)
106. Shivanand P, Binal P, Viral D. Microneedles: progress in developing new technology for painless drug delivery. IJPTR 2009;1(4):1279-82
107. Nordquist L, Roxhed N, Griss P, Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. PR 2007;24(7):1381-8 (Pubitemid 46870597)
108. Silpi C, Manish B, Kumar TR. Microneedles in transdermal drug delivery: an unique painless option. IRJP 2011;2(4):72-8
109. Drug Delivery in Diabetes: making Effective Treatment Tolerable. ONdrugDelivery Web Page. Available from: http://www.ondrugdelivery.com/ publications/diabetes.pdf [Last accessed 18 July 2012]
110. Shivanand P, Jigisha P, Kinjal P. Various emerging technologies in insulin delivery system. IJPRD 2009;1(8):1-6
111. Anhalt H, Bohannon NJV. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technology & Therapeutics 2010;12(S1):S51-S58
112. Valeritas, Inc. Web Page. Available from: http://www.valeritas.com/[Last accessed 9 August 2012]
113. V-Go Disposable Insulin Delivery Device. Valeritas, Inc. Available from: http://www.go-vgo.com/[Last accessed 30 July 2012]
114. Amin A, Shah T, Patel J, Gajjar A. Non Invasive Insulin-Annual Update on Non-Invasive Insulin Delivery Technologies. Drug Deliv Technol 2007;7(3):43-8.Available from: http://www.drugdeliverytech-online.com/ drugdelivery/200803/?pg=43#pg43 [Last accessed 30 July 2012]
115. Chen H, Zhu H, Zheng J, et al. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 2009;139:63-72
116. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release 2011;152(3):330-48
117. Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev 2008;60(10):1218-23
118. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995;269(5225):850-3
119. Tezel A, Sens A, Tuchscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001;18(12):1694-700 (Pubitemid 34020424)
120. Saroha K, Sharma B, Yadav B. Sonophoresis: an advanced tool in transdermal drug delivery system. IJCPR 2011;3(3):89-97
121. Polat BE, Blankschtein D, Langer R. Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs. Expet Opin Drug Deliv 2010;7(12):1415-32
122. Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res 2000;17(11):1354-9 (Pubitemid 32109486)
123. Transdermal Specialties, Inc. Web Page. Available from: http://www. transdermalspecialties.com [Last accessed 19 September 2012]
124. Transdermal Specialties, Inc. 2012 Offering documents. Available from: http://www.transdermalspecialties. com/pdf/TSI-2012-ppm.pdf [Last accessed 9 August 2012]
125. GlobeNewswire Web Page. Available from: http://www.globenewswire.com/ [Last accessed at 9 August 2012]
126. Kulkarni PR, Yadav JD, Vaidya KA, Gandhi PP. Transferosomes: an emerging tool for transdermal drug delivery. IJPSR 2011;2(4):735-41
127. Wadhwa S, Rawat S, Singhal S, et al. Transferosome: a versatile tool for transdermal drug delivery. JPR 2012;5(1):610-15
128. Kapsner P, Bergenstal R, Rendell M, et al. Comparative efficacy and safety of Technosphere-Insulin and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Diabetologia 2009;52(S1):abstract #982
129. Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31(11):2177-82
130. Tack CJ, Christov V, Galan BE, et al. Randomized forced titration to different doses of Technosphere-Insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008;2(1):47-57
131. Petrucci R, Amin N, Lovertin P, et al. Pulmonary function tests remain similar in patients who received technosphere insulin and in patients currently receiving standard antidiabetic therapy [abstract #919]. Diabetologia 2009;52(S1):S361
132. Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther 2011;13(12):1201-6
133. Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther 2010;12(1):49-55
134. Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol 2008;2(3):518-29
135. Nektar Therapeutics Web Page. Available from: http://www.nektar.com/Last [accessed 30 July 2012]
136. Aradigm Corp. website. Available from: http://www.aradigm.com [Last accessed 30 July 2012]
137. Alkermes Web Page. Available from: http://www.alkermes.com/[Last accessed 30 July 2012]
138. Aerogen Web Page. Available from: http://www.aerogen.com/[Last accessed 30 July 2012]
139. Aerogen, Inc. Form 10-K Annual report: United States Securities and Exchange Comission. Washington, D.C. 20549. 2005.Available from: http://www. getfilings.com/o0001104659-05-016717. html [Last accessed 30 July 2012]
140. Abbott Web Page. Available from: http://www.abbott.com/[Last accessed 30 July 2012]
141. Vectura Web Page. Available from: http://www.vectura.com/[Last accessed 30 July 2010]
142. MicroDose Therapeutx Web Page. Available from: http://mdtx.com/[Last accessed 30 July 2012]
143. Siekmeier R, Scheuch G. Diabetes treatment by inhalation of insulin-shine and decline of a novel type of therapy. In: Esquinas AM, editor. Applied technologies in pulmonary medicine. Karger; Basel: 2011. p. 77-83
144. Coremed Web Page. Available from: http://www.coremedusa.com/[Last accessed 30 July 2012]
145. BioSante Pharmaceuticals Web Page. Available from: http://www. biosantepharma.com/[Last accessed 30 July 2012]
146. Biopharmaceutiques Web Page. Available from: http://www. biopharmaceutiques. com/[Last accessed 8 July 2012]